<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="with COVID-19 include arthralgia, myalgia, and proximal weakness with elevated" exact="creatine" post="kinase (CK) level [21, 22]. Some of these manifestations"/>
 <result pre="myocarditis was noticed following treatment with hydroxychloroquine, lopinavir/ritonavir, and intravenous" exact="methylprednisolone" post="[25, 26]. An increase in the incidence of Kawasaki"/>
 <result pre="and proximal muscle weakness preceded respiratory symptom of COVID-19 Elevate" exact="Creatine" post="kinase (CK) level (25,384Â IU/L) MRI showed muscle edema"/>
 <result pre="acute myocarditis Improved with supportive care, hydroxychloroquine, lopinavir/ritonavir, and intravenous" exact="methylprednisolone" post="[25, 26] Multisystem autoinflammatory syndrome Â Cytokine storm/Secondary Hemophagocytic"/>
 <result pre="Myopathy and neuromyopathy can rarely occur following long-term treatment with" exact="chloroquine" post="and hydroxychloroquine [33]. Favipiravir can lead to hyperuricemia [34]."/>
 <result pre="neuromyopathy can rarely occur following long-term treatment with chloroquine and" exact="hydroxychloroquine" post="[33]. Favipiravir can lead to hyperuricemia [34]. Lopinavir-ritonavir-related rheumatic"/>
 <result pre="adverse events include arthralgia, back pain, osteonecrosis, and vasculitis [35]." exact="Ribavirin" post="can cause arthralgia, back pain, myositis, and exacerbation of"/>
 <result pre="adverse effects Drugs Antiviral mechanisms Rheumatic musculoskeletal adverse events Refs." exact="Chloroquine" post="and hydroxychloroquine Inhibit pH-dependent internalization and fusion of the"/>
 <result pre="Drugs Antiviral mechanisms Rheumatic musculoskeletal adverse events Refs. Chloroquine and" exact="hydroxychloroquine" post="Inhibit pH-dependent internalization and fusion of the virus with"/>
 <result pre="fusion as well as virus-endosome fusion Not reported Galidesivir Antiviral" exact="adenosine" post="nucleoside analog Not reported Ribavirin Interfere with polymerases, RNA"/>
 <result pre="fusion Not reported Galidesivir Antiviral adenosine nucleoside analog Not reported" exact="Ribavirin" post="Interfere with polymerases, RNA capping, and inosine monophosphate dehydrogenase"/>
 <result pre="(higher incidence in combination with interferon Î±) [36] Camostat mesylate" exact="Serine" post="protease inhibitor Not reported Interferon Î± and Î² Inhibit"/>
 <result pre="activates the surrounding macrophages to release reactive oxygen species and" exact="nitric oxide" post="resulting in bystander killing of surrounding uninfected cells [67]."/>
 <result pre="antiphospholipid antibody syndrome (APS), and an autoinflammatory syndrome, deficiency of" exact="adenosine" post="deaminase-2 (DADA-2) [81]. In COVID-19, a rise in neutrophil"/>
 <result pre="receptorâ€‰&amp;gt;â€‰tocilizumab, sarilumab. (8) Anti IFN Î³â€&quot;&amp;gt;â€‰emapalumab. (9) JAK inhibitorâ€&quot;&amp;gt;â€‰baricitinib, ruxolitinib," exact="tofacitinib" post="(multi-cytokine targeted therapy). CCL2 chemokine (Câ€&quot;C motif) ligand 2,"/>
 <result pre="infection: a reviewTher Clin Risk Manag2008451023103319209283 36.NaikGSTyagiMGA pharmacological profile of" exact="ribavirin" post="and monitoring of its plasma concentration in Chronic Hepatitis"/>
</results>
